LeaderPortfolio
Rothblatt
Martine Rothblatt
Rank #2287
UNITED STATESHealthcarePharmaceuticals

Martine Rothblatt

Net Worth
$1.795B
-1.43% (24h)
Martine Rothblatt is an American lawyer, author, and entrepreneur, currently serving as the Chairwoman and CEO of United Therapeutics. Her career spans diverse fields, including satellite communications, biotechnology, and medical ethics. Rothblatt founded United Therapeutics in 1996 after her daughter was diagnosed with pulmonary arterial hypertension, a life-threatening condition. Her work in developing life-saving drugs has significantly impacted the treatment of this and other diseases. In addition to her business achievements, Rothblatt is a vocal advocate for transgender rights and a proponent of transhumanism.

How to read Martine Rothblatt's profile

Public net-worth figures are estimates. They combine observable inputs—typically listed equity, disclosed transactions, and market prices—with editorial judgment where filings are incomplete (for example, private holdings, debt, or cross-holdings). For Martine Rothblatt, we anchor the narrative to Pharmaceuticals and Pharmaceuticals, then update the headline number as markets move. The chart on this page is meant to show trajectory, not a certified balance sheet.

When you see $1.795B alongside global rank #2287, interpret it as our best synthesis of widely cited ownership and price signals—not a claim about cash on hand. Estimates can diverge from other publishers because of different treatment of options, trusts, charitable vehicles, or illiquid assets. We document the general approach in methodology and welcome corrections via corrections.

Country (UNITED STATES) and career milestones on this page are curated for reader context; they should be verified against primary sources when used for research. Editorial metadata for this profile is refreshed on a rolling basis, with deeper audits at least annually (last noted cycle: 2026).

Looking for depth? When available, the dossier and timeline sections below add long-form context beyond the headline number—prioritize those modules when evaluating claims about strategy, controversies, or philanthropic commitments.

The Full Dossier

Early Life

Martine Aliana Rothblatt was born in 1954 in Chicago, Illinois, and raised in a suburb of San Diego, California. She had an early fascination with technology, which led her to a pivotal experience at a NASA tracking station in the Seychelles, inspiring her to unite the world through satellite communications.

Rise to Success

Rothblatt's career began in communications satellite law. She earned a B.A., J.D., and MBA from UCLA. She co-founded Sirius Satellite Radio in 1990, before moving into biotechnology after her daughter was diagnosed with a rare and deadly disease. This led her to found United Therapeutics in 1996, where she pioneered treatments for pulmonary arterial hypertension. The company has since expanded into other areas, including organ manufacturing and regenerative medicine. Rothblatt's leadership has guided United Therapeutics to become a leader in the biotechnology industry. Her company's 2025 revenue was $3.18 billion.

Key Business Strategies

The success of United Therapeutics can be attributed to several key strategies. The company focuses on developing and commercializing products to address unmet medical needs, particularly for chronic and life-threatening conditions. United Therapeutics emphasizes innovation, investing heavily in research and development to create new therapies. A significant portion of the company's revenue is generated by Tyvaso products. The company also embraces a public benefit corporation structure, balancing profit with social goals. Moreover, the company is experimenting with pig cloning and genetic modification to create lung transplants.

Philanthropy

Rothblatt is involved in philanthropy through the Terasem Movement Foundation, which focuses on the use of nanotechnology for human life extension. She also supports scientific research and development in cryogenics, biotechnology, and cyber consciousness.

Career Timeline

2025

United Therapeutics Revenue

Achieved total revenues of $3.18 billion.

2024

Tyvaso Revenue

Tyvaso generated $1.62 billion in revenue.

2002

FDA Approval of Remodulin

U.S. Food and Drug Administration (FDA) approved United Therapeutics' drug Remodulin.

1996

Founded United Therapeutics

Founded United Therapeutics to seek a cure for pulmonary arterial hypertension after her daughter was diagnosed with the disease.

1990

Co-founded Sirius Satellite Radio

Founded Sirius Satellite Radio to execute her vision of satellite network technology.

1981

Law Career

Graduated from UCLA with J.D. and M.B.A. degrees.

Philanthropic Impact

Medical ResearchUnknown

Terasem Movement Foundation

Supports research on nanotechnology for human life extension.

Key Business Ventures & Holdings

CompanyStakeValue
United Therapeutics Corp0.09%$0.006M

Net Worth History

In-Depth Analysis

Early Life

Martine Aliana Rothblatt was born in 1954 in Chicago, Illinois, and raised in a suburb of San Diego, California. She had an early fascination with technology, which led her to a pivotal experience at a NASA tracking station in the Seychelles, inspiring her to unite the world through satellite communications.

Rise to Success

Rothblatt's career began in communications satellite law. She earned a B.A., J.D., and MBA from UCLA. She co-founded Sirius Satellite Radio in 1990, before moving into biotechnology after her daughter was diagnosed with a rare and deadly disease. This led her to found United Therapeutics in 1996, where she pioneered treatments for pulmonary arterial hypertension. The company has since expanded into other areas, including organ manufacturing and regenerative medicine. Rothblatt's leadership has guided United Therapeutics to become a leader in the biotechnology industry. Her company's 2025 revenue was $3.18 billion.

Key Business Strategies

The success of United Therapeutics can be attributed to several key strategies. The company focuses on developing and commercializing products to address unmet medical needs, particularly for chronic and life-threatening conditions. United Therapeutics emphasizes innovation, investing heavily in research and development to create new therapies. A significant portion of the company's revenue is generated by Tyvaso products. The company also embraces a public benefit corporation structure, balancing profit with social goals. Moreover, the company is experimenting with pig cloning and genetic modification to create lung transplants.

Philanthropy

Rothblatt is involved in philanthropy through the Terasem Movement Foundation, which focuses on the use of nanotechnology for human life extension. She also supports scientific research and development in cryogenics, biotechnology, and cyber consciousness.

Data Sources & Methodology

Figures for Martine Rothblatt are synthesized from the sources below and cross-checked against our net worth methodology. Estimates may lag market moves; see corrections to report discrepancies.